A blocking enzyme-linked immunosorbent assay (ELISA) was developed to detect antibodies to equine herpesvirus 2 in serum samples of horses. By measuring the binding to a single epitope, this blocking ELISA gives a good picture of the antibody status in the animal. The test is based on a monoclonal antibody with neutralizing activity and had a sensitivity of 94% and a specificity of 100%. Antibodies due to newly acquired infection in foals were successfully detected with this blocking ELISA.
body (MAb). By measuring the binding to a single neutralizing epitope, the ELISA can replace the laborious neutralization test.
Materials and methods

Virus and cells
A Hungarian isolate of EHV-2 (strain KT-5797 22 ) was propagated in a rabbit kidney cell line . The cells were grown in Eagle minimum essential medium with Earle salts supplemented with 10% fetal calf serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin using standard tissue culture propagation methods. For immunofluorescence, equine herpesvirus type 1 (EHV-1, Bartha vaccine strain), equine herpesvirus type 3 (EHV-3, ECE 53/69), and EHV-5 (strain 2.151 7 ) were also used.
Virus purification
Cells and cell debris were removed by centrifugation at 2,000 ϫ g for 20 min at 4 C. The supernatant was concentrated 10-fold by ultrafiltration a with an exclusion limit of 100 kD. The concentrated virus was centrifuged b at 30,000 ϫ g for 90 min at 4 C. The pellet was resuspended in 500 l of phosphate buffered saline (PBS), pH 7.4, layered onto a 10-50% metrizamide gradient, c and centrifuged a at 30,000 ϫ g for 16 hr at 4 C, and the virus band was collected.
Sera from Swedish horses
Field sera from 197 Standardbred Trotters Ն1 yr of age from 2 different stables in Sweden were collected over a period of 4 yr. From stable 1 (a stable with a history of annually occurring respiratory disease problems in spring and summer that have been diagnosed as EHV-2 and R. equi; data not shown) 94 horses were sampled, and from stable 2 (without any respiratory disease problems) 103 horses were sampled. The horses were randomly chosen, and no special clinical investigation were performed. Samples were collected once from each horse. From stable 1, samples also were collected from 11 foals as follows: foal 2 at 2, 4, and 6 mo of age; foals 1, 4, 5, 7, 8, and 9 at 3, 5, and 7 mo of age; foals 3, 10, and 11 at 4, 6, and 8 mo of age; and foal 6 at 5, 7, and 9 mo of age. Mares and foals were kept apart from racing horses, although contact occasionally occurred.
Virus neutralization
Serial 2-fold dilutions of sera were prepared, and 50 l of each dilution was aliquoted into duplicate wells of flatbottom microtiter plates. d A 50-l volume of EHV-2 containing 100 TCID 50 was added, and the plates were incubated at 37 C for 4 hr. Freshly trypsinised RK-13 cell suspension (50 l, 10 4 cells/well) was added, and the plates were incubated for 7 days at 37 C. End points were determined by examining plates microscopically, and the last dilution of serum giving complete neutralization of virus-induced cytopathic effect was taken as the titer.
Preparation of MAb to EHV-2
Six Balb/C mice were immunized subcutaneously twice, 6 wk apart with 70 g of purified EHV-2 mixed with an equal volume of Freund complete or incomplete adjuvant. The animals were euthanized 4 days after the second immunization, and spleen cells were collected and fused with the myeloma cell line SP 2/0. 17 Supernatants from the hybridoma cell clones were tested on ELISA plates d coated with 3 g/ml gradient-purified EHV-2 31 . Bound antibodies were detected by a horeradish peroxidase (HRP) anti-mouse conjugate e diluted 1/1,000. Positive clones were subcloned several times, retested with the ELISA, and characterized by Western blotting, indirect immunofluorescence, and virus neutralization (VN) test. The subclones were further tested by their ability to be blocked by positive EHV-2 sera. The MAb selected for further testing was purified by immunoaffinity. 15 
Characterization of the MAb
MAb subclass determination. Subclass was determined according to the manufacturer's recommendation. b Indirect immunofluorescence. Cells were fixed and stained essentially as described previously. 13 Infected and uninfected cells grown in microtiter plates were fixed with 100% methanol, washed with PBS, and dried. The fixed cells were then incubated with the MAb (cell culture supernatant diluted 1/2 in PBS) for 1 hr, washed, incubated with a fluorescein isothiocyanate-labeled secondary anti-mouse antibody e for an additional 1 hr. The cells were then washed and observed with a fluorescence microscope.
Gel electrophoresis. The virus protein components were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 18 The M r values of the different bands were estimated by following protocols previously described. 11 Western blotting. The Western blotting method was previously described. 30 The MAb or polyclonal horse sera were tested against gradient-purified whole virus or affinity-purified protein. A nonsense MAb directed to a protein of the porcine rubula virus (La Piedad Michoacan Virus) 21 and an anti-mouse conjugate e were included as controls.
Protein purification. Virus proteins were purified using immunoaffinity chromatography. The selected MAb was coupled to CNBr-activated Sepharose 4B f according to the manufacturer's instructions and packed on a column. Tween 20 (0.5%) was added to the virus culture to disrupt the virus, which was then circulated through the column. Washing and elution steps were done according to the manufacturer's recommendation. Fractions containing eluted material were coated on a ELISA plate, d and positive fractions were detected by checking against the MAb.
Characterization of eluted protein. Positive fractions were separated by SDS-PAGE on 11% gels to determine the M r of the eluted protein and for Western blotting using polyclonal horse sera and the MAb as detecting antibody.
Blocking ELISA reagents and procedures
To perform the blocking ELISA, plates d were coated with 100 l of purified whole virus antigen overnight at 4 C at a protein concentration of 3 g/ml in 50 mM carbonate buffer, pH 9.6. Blocking was done with 2% bovine serum albumin in PBS for 1 hr at room temperature. Horse sera were diluted 1/10 in PBS containing 0.2% Tween 20 (PBST) and were allowed to react for 1 hr at room temperature. Affinity-purified MAb was diluted in PBST, added, and incubated for 1 hr at room temperature. HRP-conjugated rabbit anti-mouse e antibody was diluted in PBST, added, and incubated for 1 hr at room temperature. Substrate was 3,5,3Ј-tetramethylbenzidine and 3.5 mM H 2 O 2 in a substrate buffer (0.1 M sodium acetate, pH 6.0). The enzyme reaction was stopped after 10 min by adding 50 l of 2 M H 2 SO 4 , and the optical density (OD) was read at 450 nm with a spectrophotometer. g The results were interpreted by calculation of the percent inhibition (PI) with the following formula: 
Results
Selection and characterization of the MAb. The MAb (30A/E4) was selected for its ability to block EHV-2 sera (data not shown). Western blotting against purified EHV-2 showed that the MAb reacted with a band with an estimated M r value of 65 ( Fig. 1c) . No band was seen when probing with the nonsense MAb or with anti-mouse conjugate only (Fig. 1a, 1b) . The indirect immunofluorescence of EHV-2-infected cells showed intense staining of the membrane, whereas uninfected cell and cells infected with EHV-1, EHV-3, and EHV-5 showed no fluorescence activity (data not shown). In the VN test, cell supernatant from the clone clearly neutralized cytopathic effect from the virus at a dilution of 1/32. The subclass of the MAb was determined to be IgG1.
MAb 30A/E4 was coupled to CNBr-activated Sepharose 4B. f The chromatographic picture of the eluted protein separated by SDS-PAGE had an M r of 65 ( Fig.  1d ). Western blots with polyclonal horse sera and MAb 30A/E4 gave a band of approximate M r 65 (data not shown). Analysis of field sera. Eleven foals were sampled three times at 2-month intervals. Serum samples were tested by both the ELISA and the VN test with the aim of establishing a cutoff PI for infection. Samples with a VN titer of Ͻ1/8 had a PI of 0-19, a VN titer of 1/8 corresponded to a PI of 20-29, and VN titers of 1/16 to 1/32 corresponded to a PI of Ն30. From these data, the cutoffs were set at PI 30 for a clear positive case and Յ19 for a clear negative case. PI values of 20-29 are considered to be in the gray zone, and the horse should be retested within 2-4 weeks. All the foals had contracted an active EHV-2 infection by the age of 8 months (Fig. 2) . The foals showed a significant 4-fold antibody titer increase in the VN test and a 2-fold increase in the ELISA PI value. 9 The PI values of foals 4, 8, and 11 did not reach the cutoff of 30 but did show a 2-fold increase.
The ELISA was used to test 197 field sera. The PI values ranged from 0 to 71 and were higher in stable 1, which had a history of respiratory disease associated with EHV-2, than in stable 2, which had no clinical signs of EHV-2. Sera from horses in stable 1 had PI values between 0 and 71, and 84% of the horses had a PI of Ͼ30. Sera from horses in stable 2 had PI values between 0 and 65, and 34% of the horses had a PI of Ͼ30. The differences were significant according to a t-test.
Ninety-one of the sera from stables 1 and 2 were tested by both the ELISA and the VN test. The results of the blocking ELISA were in most cases in agreement with those of the VN test (Table 1 ). An ELISA cutoff of 30 and a VN of 1/16 were considered positive. Based on these results, the specificity and sensitivity of the blocking test were calculated: sensitivity ϭ 64/(64 ϩ 4) ϭ 94%; specificity ϭ 23/23 ϭ 100%.
Discussion
To demonstrate newly acquired EHV-2 infections, a sensitive and reliable blocking ELISA was developed using a neutralizing MAb. Stable hybridoma clones were selected by an in-house indirect ELISA. Some clones were further characterized by Western blotting and a VN test. Clone 30A/E4 was selected for its ability to block EHV-2-specific sera in an ELISA. Western blotting using the MAb 30A/E4 on gradient-purified EHV-2 revealed a band at 65 kD (Fig. 1c) . The specificity of the MAb was confirmed by indirect immunofluorescence; this MAb reacted with cells infected with EHV-2 but not with those infected with the closely related EHV-5, EHV-1, or EHV-3.
The protein reacting with MAb 30A/E4 was affinity purified by coupling of MAb to CNBr-activated Sepharose 4B. Eluted protein had an estimated M r of 65 ( Fig. 1d ). Western blotting with the MAb and polyclonal horse sera gave a band at M r 65.
Glycoprotein B is an abundant envelope glycoprotein of the alpha-and betaherpesviruses and is a major target for the immune response. 5, 23 Recently, the structure of glycoprotein B of EHV-2 was characterized 14 ; the protein is a dimer with subunits of 89 and 65/62 kD, and a neutralizing epitope was found on the 89-kD subunit. MAb 30A/E4 reacted with a band at M r 65. The MAb has neutralizing capacity and is directed to an envelope protein and may therefore be directed to an epitope on the glycoprotein B. Further studies are needed to investigate this hypothesis.
The blocking ELISA cutoff values, expressed as PI, have been determined for a selected number of negative and positive serum samples. The results of the ELISA were verified by comparing them with those obtained with the VN test. The ELISA was further evaluated on a number of Swedish horses. The ELISA had a sensitivity of 94% and a specificity of 100%. The test detected acute infections in all tested foals.
To further investigate the prevalence of EHV-2 infection, the ELISA was used to screen a large number of samples from horses of different ages (Ն1 year of age) and locations. Fifty-seven percent of the horses in 2 stables were positive for EHV-2, but the prevalence was different at the 2 stables. In stable 1, 84% of the horses had a PI value of Ͼ30. This stable had persistent problems with EHV-2 infections. In stable 2, only 34% of the horses were considered positive, and there was no history of EHV-2 infection. EHV-2 infection in young foals has been reported by others. 10, 19 In the present study, samples were obtained from 11 foals from stable 1 3 times over a period of 6 months. All foals went through an active infection of EHV-2 (Fig. 2) . Most foals probably become infected at an early age, and most of them were seropositive by 8 months of age. Some of these foals (foals 1, 4, 8, 10, and 11) did not have detectable maternal immunity between 2 and 6 months of age. In the other foals, the maternally derived antibodies could be masked by antibodies responding to the active EHV-2 infection. Horses from stables 1 and 2 are racehorses and travel repeatedly to many race tracks all over Europe. The difference in prevalence between the 2 sta-bles indicates that these horses probably get infected with EHV-2 within the stable and not at race tracks.
The blocking ELISA was shown to successfully detect antibodies generated during infections or reactivations of EHV-2.
